Identification of a high-risk group of brain metastases (BM) in patients with non-small cell lung cancer (NSCLC) could lead to early interventions and probably better prognosis. The objective of the study was to identify this group by generating a multivariable model with recognized and accessible risk factors.
A retrospective cohort from patients seen at a single center during 2010–2020, was divided into a training (TD) and validation (VD) datasets, associations with BM were measured in the TD with logit, variables significantly associated were used to generate a multivariate model. Model´s performance was measured with the AUC/C-statistic, Akaike information criterion, and Brier score.
From 570 patients with NSCLC who met the strict eligibility criteria a TD and VD were randomly assembled, no significant differences were found amid both datasets. Variables associated with BM in the multivariate logit analyses were age [P 0.001, OR 0.96 (95% CI 0.93–0.98)]; mutational status positive [P 0.027, OR 1.96 (95% CI 1.07–3.56); and carcinoembryonic antigen levels [P 0.016, OR 1.001 (95% CI 1.000–1.003). BM were diagnosed in 24% of the whole cohort. Stratification into a high-risk group after simplification of the model, displayed a frequency of BM of 63% (P < 0.001).
A multivariate model comprising age, carcinoembryonic antigen levels, and mutation status allowed the identification of a truly high-risk group of BM in NSCLC patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Open if necessary.
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33
Wang M, Wu Q, Zhang J, Qin G, Yang T, Liu Y et al (2021) Prognostic impacts of extracranial metastasis on non-small cell lung cancer with brain metastasis: a retrospective study based on surveillance, epidemiology, and end results database. Cancer Med 10(2):471–482
Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L et al (2019) Brain metastases. Nat Rev Dis Primer 5(1):5
Russell AH, Pajak TE, Selim HM, Paradelo JC, Murray K, Bansal P et al (1991) Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the radiation therapy oncology group. Int J Radiat Oncol 21(3):637–643
An N, Jing W, Wang H, Li J, Liu Y, Yu J et al (2018) Risk factors for brain metastases in patients with non-small-cell lung cancer. Cancer Med 7(12):6357–6364
Maldonado F, Gonzalez-Ling A, Oñate-Ocaña LF, Cabrera-Miranda LA, Zatarain-Barrón ZL, Turcott JG et al (2021) Prophylactic cranial irradiation in patients with high-risk metastatic non-small cell lung cancer: quality of life and neurocognitive analysis of a randomized phase II study. Int J Radiat Oncol Biol Phys 111:81
Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q et al (2014) Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol 89(2):330–337
Ouyang W, Yu J, Zhou Y, Hu J, Huang Z, Zhang J et al (2020) Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer. BMC Cancer 20(1):699
Hsiao S-H, Chung C-L, Chou Y-T, Lee H-L, Lin S-E, Liu HE (2013) Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases. Lung Cancer Amst Neth 82(2):319–323
Zhang Q, Cai X-W, Feng W, Yu W, Fu X-L (2020) Risk factors of brain metastases as initial failure in completely resected stage IIIA(N2) non-small cell lung cancer. Ann Transl Med 8(6):374
Yang B, Lee H, Um S-W, Kim K, Zo JI, Shim YM et al (2019) Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer Amst Neth 129:28–34
Mitra D, Chen Y-H, Li R, Hermann G, Atkins K, Kozono D et al (2019) EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clin Transl Radiat Oncol 18:32–38
Koh YW, Choi J-H, Ahn MS, Choi YW, Lee HW (2016) Baseline neutrophil-lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancer. Sci Rep 6:38585
Park HS, Decker RH, Wilson LD, Yu JB (2015) Prophylactic cranial irradiation for patients with locally advanced non–small-cell lung cancer at high risk for brain metastases. Clin Lung Cancer 16(4):292–297
Kamer I, Steuerman Y, Daniel-Meshulam I, Perry G, Izraeli S, Perelman M et al (2020) Predicting brain metastasis in early stage non-small cell lung cancer patients by gene expression profiling. Transl Lung Cancer Res 9(3):682–692
Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L et al (2018) Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer 19(4):e373–e379
Zhang F, Zheng W, Ying L, Wu J, Wu S, Ma S et al (2016) A nomogram to predict brain metastases of resected non-small cell lung cancer patients. Ann Surg Oncol 23(9):3033–3039
Won Y-W, Joo J, Yun T, Lee G-K, Han J-Y, Kim HT et al (2015) A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. Lung Cancer Amst Neth 88(2):201–207
Conflict of interest
None. The authors have no financial or proprietary interests in any material discussed in this article.
The retrospective nature of the study avoids any exposure to the patients; therefore, an informed consent was not required. Approval registration number CI/0676/2021.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Cacho-Díaz, B., Cuapaténcatl, L.D., Rodríguez, J.A. et al. Identification of a high-risk group for brain metastases in non-small cell lung cancer patients. J Neurooncol 155, 101–106 (2021). https://doi.org/10.1007/s11060-021-03849-w
- Brain metastases
- Lung cancer
- Predictive model
- Non-small cell lung cancer